Oral Biologics Market Size & Share, by Drug Class (Hormone, Glucagon-like Peptide (GLP-1) Receptor Agonist, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue); Disease Indication; Distribution Channel; Technology Platform; Formulation Type; Molecule Type - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

Oral Biologics Market - Regional Analysis

North America Market Insights

North America in the oral biologics market is anticipated to account for the largest share of 41.9% by the end of 2035. The market’s upliftment in the region is primarily driven by an increase in obesity prevalence, the establishment of reimbursement frameworks, the increased adoption of oral GLP-1 agonists, an expansion in Medicare and Medicaid coverage, and generous healthcare investments. According to official statistics published by the USDA Government in August 2025, there was a year-on-year (YoY) rise in adult obesity rates, especially in the U.S., by 0.6 percentage points. In addition, between March 2023 and 2024, the average adult obesity rate was 43.1%, indicating a 0.2 percentage point decrease from the 43.3% between March 2022 and 2023. Therefore, with the increased prevalence of the disorder, the market is continuously expanding in the region.

Overall U.S. Adult Obesity Yearly Rate Analysis, 2019-2024

Source: USDA Government

The oral biologics market in the U.S. is growing significantly, owing to an expansion in insurance coverage, the transition from injectable to oral drugs, federal investment in biomanufacturing, a rise in chronic diseases, regulatory modernization, and the presence of research centers. As stated in an article published by the HIV Government in February 2026, there were roughly 31,800 new HIV infections in the country, and the rate accounted for 11.3% per 100,000 people. In this regard, people injecting drugs in the country catered to 7%, which is 2,300 of the overall HIV infections as of 2022. Additionally, the male population injecting drugs constituted for 4%, which is 1,300 of the new infections, while the female population constituted for 3%, which is 1,000 of the total infections. Therefore, based on the intake of injectable drugs, the market is eventually growing in the overall country.

The increased regulatory transformation, modernization in advanced therapeutics, the provision of investments by the government, provincial health ministries, reduction in hospital admission rates for rare diseases, and suitable medication adherence are certain factors that are boosting the oral biologics market in Canada. In terms of investments, in April 2026, the Government of Canada declared a combined USD 127 million in strategic response fund (SRF) contributions to readily support 2 projects. These projects included Aspect Biosystems and Providence Health Care (PHC) in British Columbia. In addition, the government also contributed USD 79 million for supporting Aspect Biosystems, and meanwhile, the Province of British Columbia also offered USD 23.8 million to the project to ensure further expansion, thereby bolstering the market growth and demand.

APAC Market Insights

The Asia Pacific is expected to emerge as the fastest-growing region in the oral biologics market during the forecast period. The market’s development in the region is highly propelled by the high-volume manufacturing, particularly in China, along with rapid private-industry adoption in Japan, government funding, an increase in regulatory approval for novel delivery systems, and organizational contributions. For instance, in September 2024, Rigel Pharmaceuticals, Inc. entered into an exclusive supply and license agreement with Kissei Pharmaceutical Co., Ltd. for developing and commercializing REZLIDHIA® in Taiwan, Korea, and Japan. Likewise, in August 2024, UCB proclaimed a divestment deal in China for ensuring the license of its business segments, such as the Zhuhai manufacturing site, Xyzal®, Zyrtec®, Neupro®, Vimpat®, and Keppra®, thereby denoting a huge growth opportunity for the market in the region.

The oral biologics market in China is gaining increased traction, owing to growth in the manufacturing industry, localized drug availability, volume-based procurement policies, government intervention, generous investments in oral insulin, and a focus on cold-chain logistics. As stated in an article published by Xinhua in May 2026, the country’s National Medical Products Administration (NMPA) successfully approved 76 advanced drugs, indicating a record-high number, as well as a surge from the 48 approved as of 2024. Besides, since the initiation of the Provisions for Drug Registration, 629 drug registration applications have been effectively included in the approval procedure and priority review, with over 40% targeted for tumors. Moreover, the overall valuation of out-licensing deals for domestic drugs surpassed USD 60 billion, thereby positively impacting the market development.

The aspects of an increase in the incidence of lifestyle-based diseases, such as hormonal imbalances and age-related comorbidities, an increase in the elderly population, the presence of a national health system, a sudden shift from hospital-driven injectables to pharmacy-dispensed oral tablets, and suitable government support are a few trends that are responsible for fueling the oral biologics market in Japan. Besides, the Japan oral biologics market was valued at USD 151.5 million as of 2025, which is further predicted to be worth USD 185.3 million by 2026 and USD 3,690 million, along with a 39.5% growth rate by the end of 2035. Moreover, as per the Japan External Trade Organization (JETRO) article, the number of people aged more than 65 years rose to nearly 36 million as of 2023. Additionally, this is further projected to reach almost 40 million by the end of 2040, thereby making it suitable for enhancing the market demand in the country.

Elderly Population and its Share Analysis in Japan, 1950-2040

Source: JETRO

Europe Market Insights

Europe in the oral biologics market is projected to experience considerable expansion by the end of the stipulated timeline. The market’s growth in the region is effectively attributed to regulatory modernization, aging population demographics, the tactical prioritization of biosimilar adoption, and a rise in Type 2 diabetes, along with the demand for patient-friendly oral alternatives. According to official statistics published by MedTech Europe in September 2022, type 2 diabetes accounts for almost 90% of overall diabetes cases in the region. The overall pricing strategy of treatments for this particular diabetes type was worth USD 189 billion, which is 19.6% of the worldwide spending. In addition, of the overall cases, healthcare expenses in the region are owing to hospitalizations for emergencies and suitable management, thus denoting an optimistic outlook for the market growth.

The oral biologics market in Germany is gaining increased exposure, owing to the existence of a competition-based and decentralized healthcare system, the rapid adoption of advanced therapies, reimbursement pathways, the adoption of a prescription model, and the robust biosimilar and generic industry. As stated in a data report published by the World Health Organization (WHO) in 2024, the country’s health system readily serves a population of 84.7 million as of 2023. Additionally, in terms of funding mechanisms, the general fixed SHI contribution rate accounts for 14.6% of gross incomes, along with additional sickness funds catering to 1.7% as of 2024. Besides, the country significantly spent 12.7% of its gross domestic product (GDP) on health as of 2022, with expenditure amounting to USD 8,166 to health, thus proliferating the market expansion.

The existence of the centralized procurement system, strong biosimilar substitution policies, equivalent clinical profiles, an expansion in patient accessibility, the government’s Innovation 2035 plan, generous healthcare savings, eliminated cold-chain logistics expenses, and an increase in biologic prescriptions are a few factors that are enhancing the oral biologics market in France. As per a data report published by OECD in December 2025, the health system effectiveness caters to 137 per 100,000 population in terms of preventable mortality, as well as 59 per 100,000 population for treatable mortality. Besides, unmet medical demands among domestic people reported 4.5% lower needs, but 6.5% higher for people at risk of poverty. Moreover, in terms of dental care, a total of 8.2% and 13.7% account for unmet demands, thereby driving the market’s growth in the country.